| 1 |
33289516 | Bortezomib limits renal allograft interstitial fibrosis by inhibiting NF-κB/TNF-α/Akt/mTOR/P70S6K/Smurf2 pathway via IκBα protein stabilization. | 2021 Jan 15 |
1 |
| 2 |
34508613 | Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. | 2021 Sep 10 |
1 |
| 3 |
32591445 | Correction: Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IκBα degradation. | 2020 Jun 26 |
2 |
| 4 |
29279332 | Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. | 2018 Feb 16 |
1 |
| 5 |
29441489 | Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway. | 2018 Sep |
1 |
| 6 |
30024656 | Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma. | 2018 Dec |
1 |
| 7 |
30396235 | Proteasome Inhibitor-Induced IκB/NF-κB Activation is Mediated by Nrf2-Dependent Light Chain 3B Induction in Lung Cancer Cells. | 2018 Dec 31 |
1 |
| 8 |
30487672 | Ameliorating effects of bortezomib, a proteasome inhibitor, on development of dextran sulfate sodium-induced murine colitis. | 2018 Nov |
1 |
| 9 |
27923823 | Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation. | 2017 Jan |
2 |
| 10 |
27300524 | A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. | 2016 Aug |
3 |
| 11 |
27806331 | XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. | 2016 Nov 29 |
4 |
| 12 |
25633180 | 17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways. | 2015 Sep |
1 |
| 13 |
25766331 | NIK is required for NF-κB-mediated induction of BAG3 upon inhibition of constitutive protein degradation pathways. | 2015 Mar 12 |
5 |
| 14 |
26237500 | Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation. | 2015 Oct |
1 |
| 15 |
26431276 | Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk. | 2015 Oct 20 |
1 |
| 16 |
23697845 | Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. | 2014 Feb |
3 |
| 17 |
24481412 | IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. | 2014 Apr |
2 |
| 18 |
23063726 | Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. | 2013 Feb |
1 |
| 19 |
24085292 | Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner. | 2013 Nov 8 |
1 |
| 20 |
22393418 | Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells. | 2012 |
5 |
| 21 |
22819259 | Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. | 2012 Oct |
1 |
| 22 |
21174067 | Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. | 2011 Mar |
1 |
| 23 |
21224428 | Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL. | 2011 Feb |
3 |
| 24 |
21392555 | Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells. | 2011 Jun |
1 |
| 25 |
20335171 | Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. | 2010 May 21 |
7 |
| 26 |
19380866 | Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. | 2009 Jun 11 |
1 |
| 27 |
19436050 | Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. | 2009 Jul 30 |
4 |
| 28 |
18235046 | PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. | 2008 Apr 1 |
1 |
| 29 |
18776064 | Bortezomib-induced survival signals and genes in human proximal tubular cells. | 2008 Dec |
1 |
| 30 |
16733806 | Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8. | 2006 Jul |
4 |
| 31 |
17134969 | Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations. | 2006 Nov |
2 |
| 32 |
16178003 | Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. | 2005 Nov 1 |
1 |
| 33 |
15131062 | Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. | 2004 May 1 |
2 |
| 34 |
15190257 | Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. | 2004 Aug |
1 |
| 35 |
11861386 | Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. | 2002 Feb 15 |
1 |
| 36 |
12226754 | The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. | 2002 Sep 19 |
1 |